J Clin Microbiol 2003,41(5):1901–1906.PubMedCrossRef 29. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a learn more randomised trial. Lancet 2005,365(9454):123–129.PubMedCrossRef

30. EASL: [EASL clinical practice guidelines. Management of chronic hepatitis B]. Gastroenterol Clin Biol 2009,33(6–7):539–554.CrossRef 31. Papatheodoridis GV, Manolakopoulos S: EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol 2009,51(1):226–227.PubMedCrossRef 32. Stroffolini T, Gaeta GB, Mele A: AASLD Practice Guidelines on chronic hepatitis B and HBV infection in Italy. Hepatology 2007,46(2):608–609. author reply 609PubMedCrossRef 33. Arbuthnot P, Longshaw V, Naidoo T, Weinberg MS: Opportunities for treating chronic hepatitis B and C virus infection using selleck chemical RNA interference. J Viral Hepat 2007,14(7):447–459.PubMedCrossRef 34. Moore MD, McGarvey MJ, Russell RA, Cullen BR, McClure MO: Stable Selleck LCZ696 inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med 2005,7(7):918–925.PubMedCrossRef 35. Hamasaki

K, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K: Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett 2003,543(1–3):51–54.PubMedCrossRef Succinyl-CoA 36. Yu H, Yuan Q, Ge SX, Wang HY, Zhang YL, Chen QR, Zhang J, Chen PJ, Xia NS: Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype “”i”". PLoS One 2010,5(2):e9297..PubMed 37. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002,296(5567):550–553.PubMedCrossRef 38. Shiokawa T, Hattori Y, Kawano K, Ohguchi Y, Kawakami H, Toma K, Maitani Y: Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability

and antitumor effect in vitro and in vivo. Clin Cancer Res 2005,11(5):2018–2025.PubMedCrossRef 39. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996,19(11):1518–1520.PubMed 40. Sun D, Rosler C, Kidd-Ljunggren K, Nassal M: Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. J Hepatol 2010,52(6):817–826.PubMedCrossRef 41. Liang YG, Liu HY, Liu BX, Bai Y, Wu H, Zhou QH, Chen J: Detection of IFN Response of Non-Specific Effects on RNAi. Chin J Lung Cancer 2009,12(1):16–22. 42.